Medexus Pharmaceuticals (TSE:MDP) Upgraded at Raymond James

Medexus Pharmaceuticals (TSE:MDP) was upgraded by Raymond James from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday,BayStreet.CA reports. The firm presently has a C$4.00 target price on the stock, up from their previous target price of C$3.00. Raymond James’ price target points to a potential upside of 86.05% from the stock’s current price.

A number of other equities research analysts have also recently commented on MDP. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Stifel Canada upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus boosted their target price on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Trading Up 1.9 %

Shares of TSE MDP traded up C$0.04 during midday trading on Wednesday, reaching C$2.15. 17,305 shares of the company were exchanged, compared to its average volume of 41,575. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.16. The stock has a fifty day simple moving average of C$2.48 and a 200 day simple moving average of C$2.19. The stock has a market cap of C$52.74 million, a P/E ratio of 43.00 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.